Treatment of neurodegenerative ophthalmological diseases

The product, possibly an eye-drop, would be used as a treatment to reduce damages to neuronal cells caused by degenerative ophthalmological diseases (such as Glaucoma)

Title of the patent Blood serum for use in the treatment of neurodegenerative ophthalmological pathologies
Thematic area Biomedical
Ownership Alma Mater Studiorum – Università di Bologna, Azienda Ospedaliera Policlinico S. Orsola Malpighi-Bologna, Universita’ degli studi Dell’Aquila
Inventors Silvia Bisti, Marina Buzzi, Emilio Campos, Claudio Velati, Piera Versura
Protection Italy, Canada, China, Japan, Europe, US
Licensing status Available for licensing agreements
Keywords Cord blood serum, Retinal degenerative diseases, Glaucoma, Optic nerve degenerative diseases, Retina
Filed on Jun 15, 2017

Currently, the neuroprotective  treatment  of degenerative ophthalmological diseases is proposed through the administration of food supplements products or compounds of vegetal origin or specific synthetic molecules.

The invention refers to the ophthalmic use of cord blood serum (CBS) in the treatment of degenerative diseases
of the retina and the optic nerve, such as glaucoma. The product to be developed in the form of an eye-drop, will
have a neuroprotective purpose, since it will be employed to reduce early and late damage to neuronal cells
following tissue damage related to neurodegenerative diseases of retina and optic nerve. The selected growth
factors present in blood serum - especially in cord blood serum- have a strong neurotrofic effect supporting
growth and survival of neuronal cells and glia, therefore determining the neuroprotective effect of the eye-drop
to be developed.

The product to be developed could be used in the treatment of neurodegenerative diseases of the retina and optic nerve.